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Approved for public release; distribution unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Subject: Over 60% of human breast tumors display a deletion of one copy of the 1p36 region of the short arm of chromosome 1. Patients whose tumors carry this deletion show a three-fold increase in mortality, suggesting a biological role for this deletion in tumor development, and suggesting the presence of one or more tumor suppressors in this region. Purpose: Characterization of the unique biology of tumors with 1p36 deletion, and identification of the tumor suppressor(s) in the region may inform therapeutic strategies, and present unique therapeutic targets for this subset of breast cancer cases with relatively poor survival. Scope: The goals of this research project are to 1) develop a mouse model for 1p36 deletion in breast cancer by generating mice harboring loxP sequences flanking the deletion region, and crossing to tissue-specific Cre expressing mice, 2) perform in-vivo insertional mutagenesis in breast tumors using the two-component Sleeping Beauty transposon system (mutagenic transposons mobilized by a trans-acting transposase) to tag tumor suppressors and oncogenes during tumor development and 3) to combine these two systems to identify tumor suppressors in the 1p36 region. Technical setbacks and the observation by another group that deletion of at least part of the 1p36 region systemically does not lead to breast tumors in mice have led us to focus primarily on the Sleeping Beauty system for the last two years. We have opted for an in vitro approach in which we use lentiviral constructs to activate transposons in mammary epithelial cells, which we then transplant into recipient mice.
SUBJECT TERMS
1p36, insertional mutagenesis, sleeping beauty, mouse models, tumor suppressors FINAL STATUS REPORT: BC050930 C haracterizing t he R ole o f 1 p36 D eletion i n Breast Cancer and Identifying Candidate Tumor Suppressors INTRODUCTION: Subject: Over 60% of human breast tumors display a deletion of one copy of the 1p36 region of the short arm of chromosome 1. Patients whose tumors carry this deletion show a threefold increase in mortality, s uggesting a bi ological r ole f or thi s de letion in tumor de velopment, and suggesting the presence of one or more tumor suppressors in this region. Purpose: Characterization of the uni que bi ology of t umors w ith 1p36 de letion, a nd i dentification of t he t umor s uppressor(s) i n t he region may inform therapeutic strategies, and present unique therapeutic targets for this subset of breast cancer cases with relatively poor survival. Scope: The goals of this research project are to 1) develop a mouse model for 1p36 de letion in breast cancer by generating mice harboring loxP sequences flanking the deletion region, and crossing to tissue-specific Cre ex pressing mice, 2) perform in-vivo insertional mutagenesis in breast tumors using the two-component Sleeping Beauty transposon system (mutagenic transposons m obilized by a t rans-acting t ransposase) t o t ag t umor s uppressors a nd onc ogenes d uring tumor de velopment a nd 3 ) t o c ombine t hese t wo s ystems t o i dentify t umor s uppressors i n t he 1p36 region. Technical s etbacks a nd t he obs ervation by another group t hat d eletion of a t l east pa rt o f t he 1p36 region s ystemically does not lead to breast tumors in mice have led us to focus primarily o n the Sleeping Beauty system for the last two years. W hile we have been able to map transposon insertions, we have established that existing mouse constructs were inadequate to drive or accelerate tumors in the mammary gland. We have therefore opted for an in vitro approach in which we use lentiviral constructs to activate transposons in mammary epithelial cells, which we then transplant into recipient mice.
BODY:
Results from all Tasks from which we have outcomes to date from the approved Statement of Work are summarized below:
Task 1: Development of a mouse model for 1p36 deletion Aims 1A, 1B, and 1C: Obtain a nd ve rify M ICER l oxP t argeting c lones f lanking s yntenic r egion of chromosome 4 corresponding to 1p36, generate targeted ES clones, and breed doubly-targeted mice:
As s tated in the a nnual s tatus r eports f or year one a nd t wo, e arly i nto t his pr oject, another g roup published a study in which they constitutively deleted a 4 Mb region of mouse chromosome 4 within the 1p36 syntenic region (Bagchi, et al, 2007) , screened mouse embryonic fibroblast cells, and identified a candidate t umor s uppressor i n t he r egion, C HD5. While t his s creen c an be c riticized f or not be ing comprehensive in the genes screened and may not have included the region most frequently deleted in breast tumors, this was a significant result in the field. However, mice harboring this deletion have not developed breast tumors, which could suggest either the authors did not include the region most relevant to br east cancer, or t hat l oss of t his l ocus d oes not pr edispose cells i n t he m ammary gland t o transformation. Additionally, since initiating this project, we established that the HPRT-GFP construct we ha d pr oposed t o us e w as not f unctional, ne cessitating t he cloning of a ve ctor w ith an alternative marker ( the V5 epitope). F urthermore, while cloning alternative t argeting vectors, the m ouse ge nome assembly at t he t elomeric end of m ouse chromosome 4 has cha nged twice, each time ne cessitating a total refinement of our targeting strategy and setting us back several months as we cloned new targeting construct plasmids (detailed in the status reports from the first two years). T he current assembly does not map an available BAC clone to the region containing the most telomeric genes, making it difficult to clone a targeting vector that would allow us to delete all of the genes in the 1p36 locus. While we have ongoing e fforts t o c lone a l arge genomic s equence us ing l ong-range PCR on genomic D NA as a template, we ha ve not b een s uccessful t o da te. A dditionally, in s ummer 2008 my the sis committee concluded t hat, g iven t he l ong t ime hor izon f or t his pr oject a nd t he num erous t echnical s etbacks experienced to date, I needed to focus on ot her aspects of my thesis project, most notably the Sleeping Beauty insertional mutagenesis approaches outlined in Task 3.
Task 2:
Characterization of 1p36 deletion in the context of Her2-initiated oncogenesis: As stated last year, since initiation of Task 2 i s dependent on completion of Task 1, i t has not yet been initiated. However, w e ha ve i nitiated e fforts t o c ombine t he S leeping Beauty s ystem (Task 3 ) w ith MMTV-HER2/neu and MMTV-c-myc induced mammary tumors, described below.
Task 3:
Identification of candidate genes using insertional mutagenesis (months 15-36)
As described in previous reports, the Sleeping Beauty insertional mutagenesis s ystem works via a two part m echanism: 1) a t ransposon ( T2/Onc, T 2/Onc2, or T 2/Onc3), a D NA s equence capable of activating o r deactivating surrounding host genes, and 2) a transposase protein (SB10 or S B11) which excises t he T 2/Onc t ransposon a nd r e-inserts i t i nto a r andom l ocation i n t he hos t g enome. Cells harboring insertions conferring tumorigenic characteristics are selected and clonally expanded, allowing for identification of the insertion site and nearby genes.
We initially used the first-generation S B i nsertional m utagenesis s ystem, consisting of a (presumably) constitutively expressed S B10 t ransposase und er t he c ontrol of a C AGGS (beta-actin) promoter. Transgenic mice harboring this construct and a transposon transgene did not succumb to tumors without a predisposing tumor suppressor knockout (Collier, et al, 2005) . We combined this system with mice carrying the MMTV-HER2 transgene, susceptible to mammary tumors after a long latency. While we were able t o s uccessfully m ap t ransposon i nsertions, w e di d not obs erve a ny s ignificant t umor acceleration compared to mice ca rrying MMTV-HER2 a lone (described i n t he A nnual R eport f rom April 2008), nor did we see any transposase expression in tumors (described in the Annual Report from April 200 7). T he Largaespada group s ubsequently di scovered t hat t he CAGGS-SB10 c onstruct w as only e xpressed i n m uscle t issue, m ost l ikely du e t o a pos itional e ffect at the tr ansgene ins ertion site. Consistent w ith this, most of the ins ertion sites we w ere a ble to map in tumors w ere a lso present in spleens f rom t he c orresponding m ice, s uggesting t he t ransposase w as a ctive e arly i n d evelopment but dormant during tumor development.
We ne xt at tempted to increase t ransposase activity us ing a Cre-activated Rosa-SB11 knoc k-in i n combination w ith a hi gh-copy t ransposon dono r l ocus (T2/Onc2). W e a ttempted t o a ctivate t his construct with an MMTV-Cre transgenic mouse. However, consistent with other groups, we observed a high rate of leukemia formation in these mice, suggesting that the MMTV-Cre construct was active in the he matopoietic c ompartment, where the S B s ystem w as muc h more effective a t induc ing tu mors. Among the mic e that di d not s uccumb t o l eukemia, none de veloped b reast c ancer, i n s pite of the MMTV-HER2 transgene t hey carried. W e s peculate t his r esistance i s d erived from t he m ouse s train background; unlike the first generation SB system, which was on an FVB/N background susceptible to MMTV-HER2 i nduced tumors, t he s econd a nd t hird ( described be low) generations a re on a m ixed, mostly B6, genetic background that shows less susceptibility to these tumors. In parallel, we combined this system with the MMTV-c-myc model of mammary tumorigenesis. Mice in this model were even more prone to leukemia; while two mice in our screen developed solid tumors which were unlikely to have originated in the mammary gland, most mice carrying the constructs succumbed to leukemia. The high rate of leukemia in these mice prevented us from generating any reasonable collection of mammary tumors for insertion site analysis.
We next crossed MMTV-HER2 mice to mice carrying a constitutive RosaSB11 knock-in construct, in combination w ith l ow c opy t ransposons ( T2/Onc a nd T 2/Onc3, which contains a di fferent pr omoter). We hope d l eukemia i n these m ice would be m odest ( Collier, e t a l, i n review) a nd would allow f or acceleration of m ammary t umors. U nfortunately, w e ha ve onl y obs erved f our t umors t o date in m ice carrying both transposon and transposase constructs and the MMTV-HER2 transgene, a rate too low to effectively id entify common insertion sites. A dditionally, we obs erved two tumors in mice c arrying only one transposon/transposase component (i.e., negative controls), suggesting tumor acceleration may not be greatly enhanced by the transposon s ystem. T his particular conformation was also complicated by the genetic background issue described above.
In an attempt to overcome strain issues and leukemia incidence, we next turned to an in vitro/transplant based strategy. Briefly, in this system, mammary epithelial cells (MECs) are isolated from donor mice, in this cas e, mice car rying a dor mant t ransposon concatemer (T2/Onc, T 2/Onc2, or T 2/Onc3). T hese cells a re c ultured i n vi tro, a nd t he S B t ransposase i s t hen i ntroduced with a vi ral ve ctor. V irallytransduced cells are then transplanted into recipient mice in which the developing endogenous mammary epithelium ha s be en s urgically ablated. T he transduced/transplanted MECs t hen r epopulate t he mammary fat gland, forming a nor mal b ranched duc tal s ystem, such that the ma mmary epithelium is genetically modified, but the surrounding tissue is wild-type.
We f irst tr ied to implement thi s s ystem us ing MSCV-based retroviruses. A s d escribed i n last year's report, cells is olated from M MTV-HER2;T2/Onc m ice were t ransduced w ith a pM SCV-SB11-IRES-GFP (pMIG-SB11) and transplanted. Since these cells presumably had a growth advantage over normal cells (by vi rtue of t he MMTV-HER2 t ransgene), e ndogenous epithelium w as not a blated. While transplanted cells were viable (pictured in last year's report), we did not see the formation of fluorescent ducts, nor did we see clear tumor formation i n t he t ransplanted mammary glands.
We next upgraded to a l entiviralbased system. Lentiviruses can infect non-dividing cells and thus can infect the mammary stem cell subpopulation i n a M EC c ulture, providing m ore e fficient outgrowth of t ransduced c ells. Importantly, i n t his s ystem (unlike the r etroviral s ystem), transduced cells do not have to have a growth advantage to repopulate the mammary fat pad (Welm, et al 2008) . We have cloned the SB11 transposase into two lentiviral constructs, pEIZ and pEIR (Welm, et al 2008) to make the constructs pEIZ-SB11 and pEIR-SB11 ( Figure 1) . T hese c onstruct express t he t ransposase (Figure 2) and fluorescent m arkers (Figure 3 Should t his s ystem pr ove t o be e ffective a t inducing tum ors, it w ill provide a pow erful tool for f urther di ssection of br east-cancer pathways, as cells f rom an y t ransgenic or knockout donor mouse can be transduced and transplanted, a nd on e 10-week-old donor mouse can generate enough cells to transplant into 10 recipient mice in a pr ocess that takes less than a week. W e hope that the cohort of mice c urrently under obs ervation w ill generate tumors at some point within the next 8-12 m onths, at which point we can perform insertion site analysis and identify genes altered in multiple tumors and provide proof-of-principle that transposon-based insertional mutagenesis is possible in the mouse mammary gland. 
KEY RESEARCH ACCOMPLISHMENTS:
• Generation of pEIZ-SB11 and pEIR-SB11constructs.
• Successful clearing and reconstitution of mouse mammary glands.
• Generation of 20 T2/Onc2 pEIR-SB11 mice and 20 T2/Onc2;p53 +/-mice
REPORTABLE OUTCOMES:
Publications since award initiation:
Awards: AACR Scholar-in-Training Travel Award (AstraZeneca), AACR Mouse Models of Cancer Conference October 25-28, 2006.
CONCLUSION:
As of t he pr evious a nnual r eport, w e h ave de -emphasized g enerating a mosue knoc kout of t he 1p36 region, i n l ight of num erous unf oreseen t echnical di fficulties a nd t he f ailure o f a nother group t o s ee breast tumors in a similar system. As described last year, we have also acquired a wide range of tools to express t he S B11 t ransposase i n breast t issue; t wo additional m ouse constructs, and 3 nove l retroviral viral constructs. As of last year, we had generated as significant cohort of mice and have isolated over 40 tumors. We sequenced insertion sites from 11 of these tumors, and have seen indications of common insertion sites. However, most of these insertion sites were also seen in normal spleen tissue, suggesting these i nsertions di d not arise i n t he m ammary gland a nd di d not dr ive t umorigenesis. A dditionally, tumors di d not e xpress t ransposase, a nd ove rall t umor ons et w as not s ignificantly accelerated i n transposon-bearing mice. We t hen tried next-generation Sleeping B eauty expression mice. H owever, these mice either di d not ex press transposase at h igh enough levels to accelerate m ammary tumors, or expressed transposase in the hematopoietic compartment and succumbed to leukemia (or both).
We have thus adopted a lentivirus-based system in which we isolate mammary epithelial cells carrying the transposon, transduce the SB transposase with a lentivirus, and transplant the cells into donor mice. This s ystem eliminates the possibility of expression in the hematopoietic compartment while allowing high l evels of t ransposase e xpression i n m ammary e pithelial c ells. S ince t his s trategy ha s b een onl y recently cha racterized and is t echnically m ore di fficult t han breeding m ultiple g enetically en gineered mice, we have established the ability to reconstitute mammary glands with transduced and transplanted mammary epithelial cells. We are currently observing the transplant recipient mice for tumor formation, which w ill pr ovide pr oof of p rinciple in the le ntivirally-activated t ransposon-based i nsertional mutagenesis strategy in the mammary gland. This approach should provide a valuable tool with which to dissect various pathways in breast cancer.
